Abstracts tagged "Bone turnover markers"

Abstract Number: 528 • 2019 ACR/ARP Annual Meeting
Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis
Roy Fleischmann¹, Daniel Furst ², Erin Connolly-Strong ³, Jingyu Liu ³, Julie Zhu ³ and Richard Brasington ⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²University of California, Los Angeles, CA, ³Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ⁴Washington University School of Medicine in St Louis, St Louis, MO
Background/Purpose: Persistently active rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation and bone loss.1 Although short-term administration of corticosteroids (CSs) is recommended…
Abstract Number: 2547 • 2019 ACR/ARP Annual Meeting
Safety Results of 50% Enrollment from a Multicenter, Randomized, Double‑blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate‑dose Corticosteroid Use
Anca Askanase¹, Dharani Munirathinam ², Enxu Zhao ², Julie Zhu ², Erin Connolly-Strong ² and Richard Furie ³, ¹Columbia University Medical Center, New York, NY, ²Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ³Northwell Health, Great Neck, NY
Background/Purpose: Repository corticotropin injection (RCI) is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH1-39) analogues and other pituitary peptides that stimulates endogenous corticosteroid (CS)…
Abstract Number: 2304 • 2018 ACR/ARHP Annual Meeting
Implication of Bone Turnover Marker Follow-up during Antiresorptive Therapy in Patients with Active Rheumatoid Arthritis on Immunosuppresssive Agents
Seonghoon Park¹, Hwajeong Lee², Seong-Kyu Kim³ and Jung-Yoon Choe³, ¹Medicine, Daegu Catholic University School of Medicine, Daegu, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea, Republic of (South), ³Medicine, Catholic university of Daegu, School of medicine, Daegu, Korea, Republic of (South)
Background/Purpose: Changes in bone turnover marker (BTM) are known to offer an information regarding a dynamics of bone remodeling, treatment outcome in primary osteoporosis (OP).…
Abstract Number: 2312 • 2018 ACR/ARHP Annual Meeting
Spontaneous Vertebral Fractures after Denosumab Discontinuation
Helena Florez¹, Julio Ramírez², Ana Monegal¹, Núria Guañabens¹ and Pilar Peris¹, ¹Department of Rheumatology, Hospital Clinic, University of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain
Spontaneous Vertebral Fractures after Denosumab Discontinuation.H. Florez, J. Ramírez, A. Monegal, N. Guañabens, P. Peris. Department of Rheumatology. Hospital Clinic, University of Barcelona. Background/Purpose: Denosumab…
Abstract Number: 2382 • 2017 ACR/ARHP Annual Meeting
Reliability of the Biochemical Bone Markers CTX and P1NP during a TNF-Inhibitor Treatment Cycle in Patients with Rheumatoid Arthritis
Kim Holmsted¹, Niklas Rye Jørgensen² and Ole Rintek Madsen¹, ¹Center for Rheumatology and Spine Diseases & The DANBIO Registry, Copenhagen University Hospital Rigshospitalet Gentofte Glostrup, Copenhagen, Denmark, ²Dept. of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of developing osteoporosis. Dual Energy X-ray Absorptiometry (DXA) with assessment of BMD is used for…
Abstract Number: 365 • 2015 ACR/ARHP Annual Meeting
Can We Use Bone Turnover Markers As Targets for Antiresorptive Treatment in Postmenopausal Osteoporosis? an Analysis from Two Phase 3 Clinical Trials
JP Brown¹, P Dakin², P Hadji³, MR McClung⁴, PD Miller⁵, J-Y Reginster⁶, RB Wagman², A Wang² and E McCloskey⁷, ¹Laval University and CHU de Québec (CHUL) Research Centre, Quebec City, QC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³Philipps-University of Marburg, Marburg, Germany, ⁴Oregon Osteoporosis Center, Portland, OR, ⁵Colorado Center for Bone Research, Lakewood, CO, ⁶University of Liège, Liège, Belgium, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Bone turnover markers (BTMs) respond faster than bone mineral density as an indicator of response to therapy in osteoporotic patients; however, it remains unclear…
Abstract Number: 2256 • 2014 ACR/ARHP Annual Meeting
Effects of Pre-Dosage Alendronate Treatment on Bone Metabolic Indices and Bone Mineral Density in Patients Treated with Glucocorticoids: A Prospective Study
Yasuo Kuroki¹, Hiroshi Kaji², Mika Yamauchi³ and Toshitsugu Sugimoto⁴, ¹Dept of Internal Medicine, Kobe Century Memorial Hospital, Kobe, Japan, ²Department of Physiology and Regenerative Medicine, Kinki University Faculty of Medicine, Osakasayama, Japan, ³Internal Medicine 1, Shimane University Faculty of Medicine, Izmo, Japan, ⁴Internal Medicine 1, Shimane University Faculty of Medicine, Izumo, Japan
Background/Purpose: Glucocorticoids (GCs) treatment induces secondary osteoporosis characterized by rapid bone loss and an increase in fracture risk, although GCs are used to treat a…
Abstract Number: 233 • 2014 ACR/ARHP Annual Meeting
Significance of Serum Marker Levels of Wnt/ß-Catenin Signaling Pathway in Patients with Systemic Autoimmune Diseases Under Glucocorticoid Therapy; A Prospective Study
Mai Kawazoe, Kotaro Shikano, Kaichi Kaneko, Shotaro Masuoka, Hiroshi Sato, Emiko Shindo, Natsuki Fujio, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki, Tomoko Hasunuma and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including systemic autoimmune diseases. Although glucocorticoids improve the outcome for patients with these diseases,…
Abstract Number: 34 • 2014 ACR/ARHP Annual Meeting
Pro-Nerve Growth Factor (ProNGF) Stimulates Bone Growth By Stimulating Osteoblasts and Inhibiting Osteoclast Differentiation, an Explanation for Anti-NGF-Mediated Osteonecrosis; Prongf Is a Novel Therapeutic Target for Treatment of Osteonecrosis and Charcot’s Arthropathy
Aranzazu Mediero¹, Barbara Hempstead² and Bruce N. Cronstein³, ¹Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, ²Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY, ³NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose Neurotrophins (Nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF)) are initially synthesized as pro-neurotrophins (proNGF and proBDNF), which are hydrolyzed to produce the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].